TorreyPines/Axonyx Merger Will Pursue CNS Disorder Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
The merged firm will likely seek a licensing partner before submitting an NDA for Axonyx’ Alzheimer’s disease candidate phenserine.